ALLMedicine™ Bullous Pemphigoid Center

May 18th, 2022 - Rituximab is a potential initial adjuvant therapy for bullous pemphigoid, yet clinical experience is scarce. We aimed to examine the clinical outcomes and safety of initial combination therapy with systemic corticosteroids and adjuvant rituximab f...

May 13th, 2022 - Bullous pemphigoid (BP) is a rare disease mainly affecting the elderly. BP is associated with significant morbidity and increased mortality secondary to increased risk of secondary infections, comorbid conditions, and serious side effects from hig...

May 12th, 2022 - We report a patient with bullous pemphigoid (BP) who was successfully treated with dupilumab monotherapy. To clarify the underlying mechanism of this effective treatment, we investigated the dynamics of a variety of cytokine-producing T cells befo...

May 7th, 2022 - Infantile bullous pemphigoid.|2022|Cozzani E,Herzum A,Gasparini G,Viglizzo G,Parodi A,|drug therapy,

May 7th, 2022 - Journal club: Bullous pemphigoid.|2022|Rosell-Diaz A,Lefevre MA,Mohme S,Alband N,Nogueira M,|

May 13th, 2022 - Bullous pemphigoid (BP) is a rare disease mainly affecting the elderly. BP is associated with significant morbidity and increased mortality secondary to increased risk of secondary infections, comorbid conditions, and serious side effects from hig...

Jan 18th, 2022 - The study will be a phase 2, multicentre, single arm, pilot study. It has been designed to determine if DF2156A has sufficient activity to warrant its further development. A total of twelve (12) BP patients will be involved, who will be administer...

Jul 8th, 2021 - This is a randomized, double-blind, placebo-controlled study to assess the therapeutic effect and safety of adjunctive AKST4290 in subjects with bullous pemphigoid (BP). Subjects will receive topical mometasone furoate cream (MFC) therapy concurre...

Aug 20th, 2019 - So far no systematic studies exist about the prevalence and incidence of autoimmune blistering disease (AIBD) in HIV infected patients. Various case reports have been published, though the overall frequency appears to be low. The aim of this proje...

Apr 24th, 2019 - Glucocorticoids have direct effects on bone remodeling by suppressing bone formation (inhibition of osteoblastic differentiation, inhibition of mature osteoblasts function and apoptosis of mature osteoblasts) and by increasing bone resorption (dec...

Apr 21st, 2022 - Bullous pemphigoid, an immune-mediated condition chacterized by large, fluid-filled blisters on the skin, is a rare but serious complication of cancer therapy with immune checkpoint inhibitors (ICIs) that may result in treatment interruption or ce...

Dec 1st, 2021 - Direct immunofluorescence (DIF) is the go-to diagnostic test when evaluating vesiculobullous eruptions, connective tissue disease, and vasculitis. This specialized test allows visualization of autoantibodies and their reaction products in the epid.

Sep 30th, 2021 - This patient was given a diagnosis of linear IgA bullous dermatosis (LABD) based on biopsy results. (Biopsy is extremely helpful in differentiating bullous disorders.

Jul 26th, 2021 - NEW YORK (Reuters Health) - SARS-CoV-2 mRNA vaccines may trigger subepidermal blistering eruptions, particularly bullous pemphigoid and most often in older adults, U.S. clinicians report. However, "given the risks of SARS-CoV-2 infection, the rari...

Jun 16th, 2021 - Granuloma annulare (GA) is a benign, cutaneous, granulomatous disease of unclear etiology. Typically, GA presents in young adults as asymptomatic, annular, flesh-colored to pink papules and plaques, commonly on the upper and lower extremities.